Anamorelin
Also known as: Adlumiz, AN-202, ANAM, Anamorelin HCl, Megalyn, ONO-7643, RC-1291
Source Anamorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Anamorelin is an oral ghrelin receptor agonist developed for the treatment of cancer‑related cachexia. It increases appetite, body weight and lean body mass by stimulating GH secretion.
Mechanism of Action
Selective agonist of the ghrelin receptor (GHSR1a) that stimulates growth hormone release and increases appetite and food intake
Routes of Administration
Goals & Uses
- Weight gain / lean body massNutritional SupportHigh
- Cancer cachexia treatmentMetabolic/OncologyHigh
- Increase appetiteSymptom ControlHigh
- Quality of life improvement in cancer patientsSupportive OncologyModerate
- Improve quality of lifePatient‑reported OutcomeModerate
- Growth hormone secretionEndocrineHigh
- Lean body mass preservationBody CompositionHigh
- Appetite stimulationNutritionalHigh
Contraindications
- Concurrent strong CYP3A4 inhibitorsDrug InteractionModerate
- Active malignancy with hormone-sensitive tumorsOncologyModerate
- Hypersensitivity to anamorelinAllergyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Diabetes mellitus (uncontrolled)MetabolicModerate
- Hypersensitivity to anamorelin or any excipientsAllergyHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- QTc prolongationCardiacUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Elevated IGF-1EndocrineCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
- Increased appetiteMetabolicCommon
Drug Interactions
- CYP3A4 inducers (e.g., rifampin)Moderate
- CYP3A4 inhibitors (e.g., ketoconazole)Moderate
- Insulin / antidiabetic agentsModerate
- Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine)Moderate
- QT-prolonging agents (e.g., antiarrhythmics, some antibiotics)Moderate
- Insulin or antidiabetic agentsLow
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)High
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- Elderly patients (>75 years)AgeRelative
- Patients with uncontrolled diabetesMetabolicRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in the European Union.
- JPApprovedApproved: cancer cachexiaApproved in Japan (2021) as oral formulation for cancer‑related cachexia.
- United StatesInvestigationalCompleted Phase III trials; not approved by FDA.
- United KingdomUnapprovedNot approved by MHRA; follows EMA negative opinion pre-Brexit.
Approved in Japan for cancer cachexia; not approved in the US or EU, currently under investigation in other regions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Anamorelin?
Anamorelin is an oral ghrelin receptor agonist developed for the treatment of cancer‑related cachexia. It increases appetite, body weight and lean body mass by stimulating GH secretion.
What is Anamorelin used for?
Anamorelin is educationally associated with: Weight gain / lean body mass, Cancer cachexia treatment, Increase appetite, Quality of life improvement in cancer patients, Improve quality of life, Growth hormone secretion, Lean body mass preservation, Appetite stimulation. Educational only — not medical advice.
How is Anamorelin administered?
Recorded routes of administration: Oral.
What are the potential side effects of Anamorelin?
Reported adverse effects include: Edema, Peripheral edema, Hyperglycemia, QTc prolongation, Nausea, Fatigue, Elevated IGF-1, Diarrhea, Dizziness, Increased appetite. This list is not exhaustive — consult a qualified clinician.
Who should avoid Anamorelin?
Recorded contraindications: Concurrent strong CYP3A4 inhibitors, Active malignancy with hormone-sensitive tumors, Hypersensitivity to anamorelin, Severe hepatic impairment, Diabetes mellitus (uncontrolled), Hypersensitivity to anamorelin or any excipients. Consult a qualified clinician before use.